Maureen Canavan, PhD, MPH
Cards
About
Titles
Associate Research Scientist (General Medicine)
Affiliated Faculty, Yale Institute for Global HealthBiography
Maureen E. Canavan, Ph.D., is an epidemiologist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) since 2017. In addition to working the MCBS data, she works as part of the Yale Cancer Center’s Cancer Care Innovations Lab (CaCIL) team evaluating quality metrics for cancer care. Her research interests include health management, employment, and end of life care. Prior to her work at COPPER, she was a member of the Global Health Leadership Institute (GHLI) team, she conducts qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China. She received an M.P.H. from the University of Medicine and Dentistry of New Jersey, School of Public Health and a B.S. from Pennsylvania State University.
Appointments
General Internal Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
- COPPER Center
- General Internal Medicine
- Internal Medicine
- Obesity Research Working Group
- Yale Institute for Global Health
Education & Training
- PhD
- Yale University Graduate School (2011)
- MPH
- University of Medicine and Dentistry of New Jersey, School of Public Health, Epidemiology, Health Education, and Behavioral Science (2005)
- BS
- Pennsylvania State University, Biology (2003)
Research
Publications
2024
Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024 PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsSurgical and Endoscopic Management of Clinical T1b Esophageal Cancer
Ayoade O, Canavan M, De Santis W, Zhan P, Boffa D. Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38925509, DOI: 10.1016/j.jtcvs.2024.06.011.Peer-Reviewed Original ResearchEsophageal cancerTumor attributesEsophagectomy patientsEndoscopic treatmentAccelerated time failure modelsEndoscopic managementTumor size > 1 cmFactors associated with upstagingOccult lymph node metastasisAssociated with improved survivalAssociated with lymphovascular invasionEffect of esophagectomyT1b esophageal cancerTreatment naive patientsNational Cancer DatabaseWell-differentiated tumorsKaplan Meier analysisLymph node metastasisPoor tumor differentiationTime failure modelsNodal upstagingLymphovascular invasionOverall survivalEndoscopic patientsMeier analysisSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapySystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10 PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioAssociation of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regressionSources of Contraception Among Adolescents and Young Adults
Shankar M, Wood S, Sharifi M, Costa D, Canavan M, McNamara M, Camenga D. Sources of Contraception Among Adolescents and Young Adults. JAMA Pediatrics 2024, 178: 502-504. PMID: 38526498, PMCID: PMC10964153, DOI: 10.1001/jamapediatrics.2024.0111.Peer-Reviewed Original ResearchSalvage Lung Resection after Immunotherapy is Feasible and Safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage Lung Resection after Immunotherapy is Feasible and Safe. JTCVS Open 2024 DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patients
2023
Awareness of racial/ethnic inequities in time to treatment among breast cancer providers.
Cohen I, Canavan M, Jacob A, Sondhi A, Silver H, Bramwell L, Lustberg M, Adelson K. Awareness of racial/ethnic inequities in time to treatment among breast cancer providers. JCO Oncology Practice 2023, 19: 584-584. DOI: 10.1200/op.2023.19.11_suppl.584.Peer-Reviewed Original ResearchBreast cancer providersCancer providersRace/ethnicityEthnic inequitiesTreatment inequitiesExact testSmilow Cancer HospitalYale Cancer CenterHospital-level factorsEducational interventionAdverse social determinantsFisher's exact testDe-identified databaseBrief educational interventionNon-Latinx WhitesPatient factorsWhite patientsProvider factorsCancer HospitalCancer CenterCancer patientsOncological careCare metricsClinical armTreatment metricsRespect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matchingAssessment of a collaborative treatment model for trimodal management of esophageal cancer
Udelsman B, Ermer T, Ely S, Canavan M, Zhan P, Boffa D, Blasberg J. Assessment of a collaborative treatment model for trimodal management of esophageal cancer. Journal Of Thoracic Disease 2023, 15: 4668-4680. PMID: 37868899, PMCID: PMC10586936, DOI: 10.21037/jtd-23-346.Peer-Reviewed Original ResearchPathologic complete responseNational Cancer DatabaseGy of radiationEsophageal cancerCollaborative treatmentCollaborative treatment modelMultiagent chemotherapySingle institutionRate of pCRPatient travel burdenR0 resection rateTreatment modelTrimodality therapyTrimodality treatmentNeoadjuvant chemoradiotherapyNeoadjuvant therapyR0 resectionResection rateComplete responseMultivariable analysisTumor characteristicsCancer DatabaseMedian travel distancePatientsCollaborative Cohort
Academic Achievements and Community Involvement
Links & Media
News
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- May 17, 2024Source: NewsBreak
Most cancer treatments are useless for patients with advanced tumors near end of life
- May 16, 2024
Oncologists Should Re-Evaluate Cancer Treatments Near End of Life
- March 25, 2024
Contraceptive Access for Adolescents and Young Adults Varies Across Different Demographics